For more information or to enroll in these trials, please contact the Stanford Pituitary Center at: 650-723-3551
If you or any family members have been diagnosed with acromegaly, you might be interested in our clinical trial. We are currently conducting a research study with an investigational drug, pasireotide (SOM230) in patients with active acromegaly. This study is a multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly. You may be eligible to participate if you are at least 18 years of age and have been diagnosed with acromegaly but have never had any medical treatment. Once eligible, you will receive a total of 12 intra-muscular injections of either pasireotide or octreotide every 28 days during the 12-month treatment period of this trial.
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. in patients with de novo, persistent or recurrent Cushing’s disease
If you have been diagnosed with Cushing’s disease (Cushing’s syndrome due to a pituitary tumor) and need an alternative medical treatment option, then you might be interested in participating in our clinical trial. This study is designed to assess the efficacy of a new investigational drug, SOM230, in patients with newly diagnosed, persistent, or recurrent Cushing’s disease. This study is currently being conducted at 36 centers all over the world, and Stanford is one of the centers involved in this study. We are recruiting both male and female ≥ 18 years of age, with confirmed diagnosis of ACTH-dependent Cushing’s disease. Patients with newly diagnosed Cushing’s disease can be included only if they are not considered immediate candidates for pituitary surgery. Patients who fulfill the entrance criteria will be randomized in a double-blinded manner to receive a preselected dose of SOM230 subcutaneously for over a 12-month treatment period with the option to continue in an extension study.
An Open Label Study of the Efficacy and Safety of CORLUX (mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing’s syndrome
We are recruiting for patients diagnosed with Cushing’s syndrome to participate in a clinical trial of a new investigational drug. This study is designed to assess the safety and efficacy of mifepristone (a glucocorticoid receptor blocking agent) in the treatment of the signs and symptoms of Cushing’s syndrome. This study will enroll subjects with clinically significant hypercortisolemia who have not responded adequately to surgical or radiation treatment for Cushing’s syndrome, or who cannot undergo surgery. To be eligible for inclusion, subjects must have documented evidence of persistent endogenous hypercortisolemia. We are recruiting both male and female ≥ 18 years of age with a confirmed diagnosis of endogenous hypercortisolemia due to any tumor cause, including pituitary, adrenal, or carcinoid tumors. Patients who fulfill the entrance criteria will receive mifepristone at doses from 300 mg/day to 1200 mg/day daily for up to 24 weeks.